何煦芳,全会标,魏伟平,张华川,陈道雄,方团育,陈开宁.艾塞那肽联合二甲双胍治疗新诊断超重或肥胖2型糖尿病的疗效及后续观察.[J].中南医学科学杂志.,2017,(4):369-373.
艾塞那肽联合二甲双胍治疗新诊断超重或肥胖2型糖尿病的疗效及后续观察
Observation on combination of exenatide and metformin treating newly- diagnosed type 2 diabetic patients that are overweight or obese
投稿时间:2016-12-29  修订日期:2017-05-30
DOI:10.15972/j.cnki.43-1509/r.2017.04.010
中文关键词:  2型糖尿病  肥胖  艾塞那肽  二甲双胍
英文关键词:type 2 diabetes mellitus  obesity  Metformin
基金项目:海南省重点科技计划项目资助ZDXM20120046. 
作者单位
何煦芳 海南边防总队医院内科,海南 海口 570208 
全会标 海南省人民医院内分泌科 
魏伟平 海南省人民医院内分泌科 
张华川 海南省人民医院内分泌科 
陈道雄 海南省人民医院内分泌科 
方团育 海南省人民医院内分泌科 
陈开宁 海南省人民医院内分泌科 
摘要点击次数: 791
全文下载次数: 564
中文摘要:
      目的 评估艾塞那肽联合二甲双胍治疗新诊断超重或肥胖2型糖尿病(T2DM)患者的疗效及安全性,以及停用艾塞那肽12周后患者各项指标的变化。方法 选取新诊断超重或肥胖T2DM患者50例为研究对象,检测治疗前及艾塞那肽联合二甲双胍治疗12周后患者体重、血糖、C肽、胰岛素、脂联素、C反应蛋白(CRP)、肿瘤坏死因子(TNF-α)及抵抗素以及其他血液生化指标,而后停用艾塞那肽12周,再重复检测上述指标。结果艾塞那肽联合二甲双胍治疗改善了患者胰岛素抵抗和分泌功能,有效降低患者血糖(P<0.01),安全性好,低血糖发生率低,同时可减轻患者体重(P<0.01),升高患者脂联素水平(P<0.05),降低CRP(P<0.05)、TNF-α(P<0.01)及抵抗素水平(P<0.05)。即使停用艾塞那肽12周,患者体重也没有明显反弹(P>0.05),除血糖较前稍升高外(P<0.01),其余指标无显著变化。结论对新诊断超重或肥胖T2DM患者,艾塞那肽联合二甲双胍是安全、有效、优化的治疗方案,并且对患者体重及胰岛素抵抗的改善可产生一定的后续效应。
英文摘要:
      Objective Objective This study evaluates the efficacy and safety of combination of Exenatide and metformin in the treatment of newly-diagnosed type 2 diabetic patients with overweight or obesity,and the change of indicators in patients after 12 weeks of withdrawal of Exenatide.Methods50 overweight or obese patients were chosen to detect body weight,blood glucose,C-peptide,Insulin,adiponectin,C-reactive protein,Tumor Necrosis Factor-а,resistin and other biochemical markers in blood before and 12 weeks after treatment.Detection were also repeated after 12 weeks of Exenatide withdrawal.ResultsInsulin resistance and secreting function were well-improved with the treatment of Exenatide and metformin.Blood glucose was reduced effectively and safely with low incidence of hypoglycemia(P<0.01).at the same time,weight loss(P<0.01),increase of adiponectin(P<0.05),decrease of CRP(P<0.05),TNF-α(P<0.01)and resistin(P<0.05) were also displayed during observation.There was no obvious weight regain or changes in other indicators even after 12 weeks of Exenatide withdrawal except a slight rise in blood glucose(P<0.01).ConclusionThe combination of Exenatide and Metformin is a safe,effective and optimized treatment for type 2 diabetic patients that are either overweight or obese.It also demonstrates legacy effects on weight management and improvement of insulin resistance.
查看全文  查看/发表评论  下载PDF阅读器
关闭
function PdfOpen(url){ var win="toolbar=no,location=no,directories=no,status=yes,menubar=yes,scrollbars=yes,resizable=yes"; window.open(url,"",win); } function openWin(url,w,h){ var win="toolbar=no,location=no,directories=no,status=no,menubar=no,scrollbars=yes,resizable=no,width=" + w + ",height=" + h; controlWindow=window.open(url,"",win); } &et=065A03FA1B5E9FC3090984CB866BD18454A60D4294957812BB4D9476F1236803F6285880446FAECFEE3A9C50DBA6180974E9984DC4474926A258FE015F1D314706FC368AA1D5514490A929F332C27BA093396C7A4E71FBE0BA9F38B2C6E52F7DD6045E3EA3F2793582DF23F3411DBC297174317AE817666B39A3999E3DFE87963E5C8194701B54E3&pcid=A9DB1C13C87CE289EA38239A9433C9DC&cid=BB33F1C95224820A&jid=6A20DF2A798996E24F064D5ECF83A153&yid=FA004A8A4ED1540B&aid=C939721BD82FFD06CA5D8918BD3504E6&vid=&iid=E158A972A605785F&sid=F7BB24011DC0D223&eid=F4BDB5452F9F5642&fileno=20170410&flag=1&is_more=0">